Most patients completed at-home chemotherapy infusions as planned, and no one stopped treatment because of adverse drug reactions.
The cancer incidence in certain immunocompromised patients was almost twice as high as the age-adjusted cancer incidence in the general population.
Patients who did not receive EGFR TKIs had a significantly higher risk of dying or needing subsequent treatment.
First-line pembrolizumab plus nab-paclitaxel may improve some outcomes over chemotherapy alone in advanced triple-negative breast cancer.
Late relapse of triple-negative breast cancer is associated with biological factors but not sociodemographic factors, a study suggests.
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Patients with perineural invasion had a 4-fold higher risk of biochemical recurrence.
Patients in the very high risk group had a significantly higher risk of recurrence, metastasis, and death.
Although mortality-to-incidence indices are improving globally, the increasing burden of AML is “concerning,” according to researchers.
There was no significant difference in post-infusion hospitalizations between patients with and without a history of cancer.
Researchers evaluated the effects of an after-hours nurse triage phone program, extended hours for infusion services, and a cancer-specific urgent care center.
A greater likelihood of socioeconomic disadvantages may help explain the poor survival outcomes observed in patients with small-cell lung cancer, according to researchers.
Recurrence rates were highest among patients who received at least 70% of treatments before noon.
Researchers discovered actionable germline genetic variants in 20% of patients who did not meet genetic testing criteria according to prior guidelines.
Patients living in warmer climates were more likely to achieve a pathologic complete response and had a lower risk of death.